XML 14 R6.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities:    
Net loss $ (45,920) $ (70,995)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,130 3,313
Stock-based compensation 5,518 15,413
Amortization of premiums and accretion of discounts on marketable securities (1,170) (3,785)
Amortization of right-of-use assets 2,003 1,757
Amortization of debt discount and debt issuance costs 159 140
Impairment of right-of-use assets and leasehold improvements 0 1,151
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 3,139 (478)
Other assets 33 50
Accounts payable 592 2
Accrued liabilities and accrued clinical supply costs (13,791) (16,507)
Payable to collaboration partner (13,572) 693
Deferred revenue (4,366) (11,548)
Refund liability to collaboration partner (15,438) (26,063)
Lease liabilities (3,634) (3,182)
Other long-term liabilities 287 210
Net cash used in operating activities (84,030) (109,829)
Cash flows from investing activities:    
Purchase of property and equipment (149) (30)
Purchase of marketable securities (79,656) (131,879)
Maturities of marketable securities 157,873 250,385
Sale of marketable securities 0 2,981
Net cash provided by investing activities 78,068 121,457
Cash flows from financing activities:    
Proceeds from the exercise of options to purchase common stock 27 0
Purchase of common stock under employee stock purchase plan 48 122
Net cash provided by financing activities 75 122
Net increase (decrease) in cash, cash equivalents, and restricted cash (5,887) 11,750
Cash, cash equivalents, and restricted cash at beginning of period 67,648 34,867
Cash, cash equivalents, and restricted cash at end of period 61,761 46,617
Supplemental Disclosures:    
Cash paid for interest $ 404 $ 216